Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 3.08
LTS's Cash-to-Debt is ranked lower than
65% of the 706 Companies
in the Global Capital Markets industry.

( Industry Median: 9999.00 vs. LTS: 3.08 )
Ranked among companies with meaningful Cash-to-Debt only.
LTS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.48 Max: No Debt
Current: 3.08
Equity-to-Asset 0.67
LTS's Equity-to-Asset is ranked higher than
59% of the 658 Companies
in the Global Capital Markets industry.

( Industry Median: 0.54 vs. LTS: 0.67 )
Ranked among companies with meaningful Equity-to-Asset only.
LTS' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.11  Med: 0.47 Max: 0.76
Current: 0.67
-1.11
0.76
Beneish M-Score: -2.52
WACC vs ROIC
11.86%
-9.19%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -0.92
LTS's Operating Margin % is ranked lower than
73% of the 689 Companies
in the Global Capital Markets industry.

( Industry Median: 14.06 vs. LTS: -0.92 )
Ranked among companies with meaningful Operating Margin % only.
LTS' s Operating Margin % Range Over the Past 10 Years
Min: -16.53  Med: -1.74 Max: 10.59
Current: -0.92
-16.53
10.59
Net Margin % -2.51
LTS's Net Margin % is ranked lower than
75% of the 690 Companies
in the Global Capital Markets industry.

( Industry Median: 10.13 vs. LTS: -2.51 )
Ranked among companies with meaningful Net Margin % only.
LTS' s Net Margin % Range Over the Past 10 Years
Min: -17.4  Med: -1.5 Max: 10.04
Current: -2.51
-17.4
10.04
ROE % -16.61
LTS's ROE % is ranked lower than
90% of the 697 Companies
in the Global Capital Markets industry.

( Industry Median: 4.37 vs. LTS: -16.61 )
Ranked among companies with meaningful ROE % only.
LTS' s ROE % Range Over the Past 10 Years
Min: -41.92  Med: -12.65 Max: 22.78
Current: -16.61
-41.92
22.78
ROA % -5.27
LTS's ROA % is ranked lower than
86% of the 712 Companies
in the Global Capital Markets industry.

( Industry Median: 1.48 vs. LTS: -5.27 )
Ranked among companies with meaningful ROA % only.
LTS' s ROA % Range Over the Past 10 Years
Min: -19.02  Med: -3.02 Max: 11.63
Current: -5.27
-19.02
11.63
3-Year Revenue Growth Rate 12.20
LTS's 3-Year Revenue Growth Rate is ranked higher than
65% of the 540 Companies
in the Global Capital Markets industry.

( Industry Median: 5.00 vs. LTS: 12.20 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LTS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -47.3  Med: 25.75 Max: 313.8
Current: 12.2
-47.3
313.8
3-Year EBITDA Growth Rate -3.20
LTS's 3-Year EBITDA Growth Rate is ranked lower than
66% of the 417 Companies
in the Global Capital Markets industry.

( Industry Median: 8.70 vs. LTS: -3.20 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LTS' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -39.5  Med: -15.5 Max: 140.1
Current: -3.2
-39.5
140.1
3-Year EPS without NRI Growth Rate 93.50
LTS's 3-Year EPS without NRI Growth Rate is ranked higher than
90% of the 408 Companies
in the Global Capital Markets industry.

( Industry Median: 7.00 vs. LTS: 93.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
LTS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -39.8  Med: 7.7 Max: 139.6
Current: 93.5
-39.8
139.6
GuruFocus has detected 1 Warning Sign with Ladenburg Thalmann Financial Services Inc $LTS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LTS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-05 Est.)


Revenue & Net Income
Equity & Asset
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

LTS Guru Trades in Q2 2016

Jim Simons 250,900 sh (+215.60%)
Murray Stahl 14,700 sh (unchged)
» More
Q3 2016

LTS Guru Trades in Q3 2016

Jim Simons 366,700 sh (+46.15%)
Murray Stahl 14,700 sh (unchged)
» More
Q4 2016

LTS Guru Trades in Q4 2016

Jim Simons 432,700 sh (+18.00%)
Murray Stahl 14,700 sh (unchged)
» More
Q1 2017

LTS Guru Trades in Q1 2017

Murray Stahl 14,700 sh (unchged)
Jim Simons 408,300 sh (-5.64%)
» More
» Details

Insider Trades

Latest Guru Trades with LTS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Ladenburg Thalmann Financial Services Inc

SymbolPriceYieldDescription
LTS.PRA25.097.978 % Cum Red Pfd Shs Series -A

Business Description

Industry: Brokers & Exchanges » Capital Markets    NAICS: 523120    SIC: 6211
Compare:NAS:COWN, OTCPK:CCORF, NYSE:GCAP, OTCPK:CAPP, NYSE:OPY, OTCPK:GMPXF, NAS:INTL, NYSE:GHL, NYSE:AC, NYSE:ITG, NAS:AMRK, NYSE:PJT, NAS:FBRC, OTCPK:PLSQF, NYSE:JMP, OTCPK:CURN, NAS:SIEB, NYSE:DFIN, OTCPK:FGCO, NAS:NHLD » details
Traded in other countries:LT6.Germany,
Headquarter Location:USA
Ladenburg Thalmann Financial Services Inc and its subsidiaries are engaged in independent brokerage and advisory services, investment banking, investment research, institutional sales and trading, asset management services and trust services.

Ladenburg Thalmann Financial Services Inc is a United States-based company that provides diversified financial services. The company conducts operations through a number of subsidiaries, with three operating segments. The independent brokerage and advisory services segment consists of broker-dealer and investment advisory services, along with wealth-management services. The Ladenburg segment comprises investment banking, sales and trading and asset-management services, and investment activities. The insurance brokerage segment comprises wholesale insurance brokerage activities. The company generates the majority of revenue from the independent brokerage and advisory services segment. Its business is concentrated in the United States.

Top Ranked Articles about Ladenburg Thalmann Financial Services Inc

ChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li Ka-shing
Gladstone Investment Corporation Announces Common Stock Offering
ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering
Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering
Amedica Announces Pricing of $11 Million Public Offering

SALT LAKE CITY, UT--(Marketwired - Jul 5, 2016) -  Amedica Corporation (NASDAQ: AMDA), a company that develops and commercializes silicon nitride ceramics, today announced the pricing of an underwritten public offering of units for gross proceeds of $11 million, prior to deducting underwriting discounts and commissions and offering expenses payable by Amedica. The offering is comprised of Class A Units, priced at a public offering price of $1.00 per unit, with each unit consisting of one share of common stock and one five-year warrant (each, a "warrant") to purchase one share of common stock with an exercise price of $1.00 per share, and Class B Units, priced at a public offering price of $1,000 per unit, with each unit comprised of one share of preferred stock which is convertible into 1,000 shares of common stock and 1,000 warrants. The conversion price of the preferred stock issued in the transaction as well as the exercise price of the warrants are fixed priced and do not contain any variable pricing features nor any price based anti-dilutive features. The preferred stock issued in this transaction includes a beneficial ownership blocker but has no dividend rights (except to extent dividends are also paid on the common stock), liquidation preference or other preferences over common stock. The securities comprising the units are immediately separable and will be issued separately. The closing of the offering is expected to take place on or about July 8, 2016, subject to the satisfaction or waiver of customary closing conditions. Ladenburg Thalmann & Co. Inc., a subsidiary of Ladenburg Thalmann Financial Services Inc. (NYSE MKT: LTS), and Maxim Group LLC are acting as joint book-running managers in connection with the offering. A total of 3,608,000 shares of common stock, 7,392 shares of preferred stock convertible into 7,392,000 shares of common stock, and warrants to purchase 11,000,000 shares of common stock will be issued in the offering. In addition, Amedica has granted the underwriters a 45-day option to purchase up to 1,650,000 additional shares of common stock and/or additional warrants to purchase up to 1,650,000 shares of common stock solely to cover over-allotments, if any, at the public offering price per share and warrant less the underwriting discounts and commissions. The securities were offered pursuant to a registration statement on Form S-1 (File No. 333-211520), which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 1, 2016. This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor will there be any sales of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. A final prospectus relating to this offering will be filed by Amedica with the SEC. When available, copies of the final prospectus can be obtained at the SEC's website at www.sec.gov or from Ladenburg Thalmann & Co. Inc., Prospectus Department, 570 Lexington Avenue, 11th Floor, New York, New York 10022, by calling (212) 409-2000 or from Maxim Group LLC, 405 Lexington Avenue, 2nd Floor, New York, NY 10174 by calling (212) 895-3745. About Amedica Corporation

Amedica is focused on the development and application of interbody implants manufactured with medical-grade silicon nitride ceramic. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty as well as dental applications. The Company's products are manufactured in its ISO 13485 certified manufacturing facility and through its partnership with Kyocera, one of the world's largest ceramic manufacturers. Amedica's FDA-cleared and CE-marked spine products are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM and private label partnerships. For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com. Forward-Looking Statements

This press release contains statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. These statements and similar statements are subject to risks and uncertainties such as changes in the market impacting the ability of the Company to close the expected offering. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found in Amedica's Risk Factors disclosure in its Annual Report on Form 10-K, filed with the Securities and Exchange Commission (SEC) on March 23, 2016, and in Amedica's other filings with the SEC. Amedica disclaims any obligation to update any forward-looking statements.


Contacts:

Mike Houston

VP, Commercialization

801-839-3534

[email protected]





Read more...
Lightstream Provides Update on Second Lien Note Interest Payment and Extension of Annual Meeting Date

CALGARY, ALBERTA--(Marketwired - Jun 14, 2016) - Lightstream Resources Ltd. (the "Company" or "Lightstream") (TSX:LTS) announces that we have chosen to defer our US$32.1 million semi-annual interest payment due June 15, 2016 in respect to our outstanding 9.875% second lien notes ("Secured Notes"). Pursuant to the indenture governing the Secured Notes, we have until July 15, 2016 (30 days) to make the interest payment before an event of default occurs. In addition, we are postponing our Annual General Meeting and we now intend to hold the meeting on or before August 31, 2016. As previously disclosed, we are focused on our liquidity situation and have been engaged in discussions with the holders of a majority of the aggregate principal amount of Secured Notes as well as certain holders of our 8.625% unsecured notes ("Unsecured Notes"), regarding a possible restructuring of the Secured Notes and Unsecured Notes, including a conversion of this debt to equity. We are also continuing to pursue asset sales to address our balance sheet and liquidity position. In addition, we remain in discussions with our syndicate of lenders under our secured term credit facility regarding the restructuring and other strategic efforts. The Company has cash on hand, currently in excess of $20 million, and monthly oil and gas sales revenue which averaged $24 million per month for the previous two months. We are continuing to pay all service providers, suppliers and contractors in the normal course of business as we pursue our strategic balance sheet initiatives. With a view to reducing the expense and inconvenience to shareholders associated with holding two separate meetings, Lightstream sought and received an extension from the TSX to postpone our Annual General Meeting to as late as August 31, 2016 in order to accommodate any shareholder vote required for a potential strategic transaction. We will issue a press release when the record date and meeting date have been determined. Lightstream Resources Ltd. is an oil and gas exploration and production company focused on light oil in the Bakken and Cardium resource plays. We are committed to delivering industry leading operating netbacks, strong cash flows and consistent operating results through leading edge technology applied to a multi-year inventory of existing and emerging resource play opportunities. Our long-term strategy is to efficiently develop our assets and deliver an attractive dividend yield. Forward-Looking Statements. Certain information provided in this press release constitutes forward-looking statements. Specifically, this press release contains forward-looking statements relating to the timing of our annual general meeting, our pursuit of strategic initiatives, including restructuring of subordinated debt and asset sales, and sufficiency of cash to fund ongoing operations. The forward-looking statements are based on information currently available as well as certain expectations and assumptions concerning anticipated financial performance, business prospects and general market conditions. Although we believe that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because we can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, our inability to implement strategic initiatives in the near term or at all to mitigate liquidity risk and avoid default under our debt agreements, commodity price and exchange rate fluctuations, general conditions in the oil and gas industry and general economic conditions. Certain of these risks are set out in more detail in our Annual Information Form which has been filed on SEDAR and can be accessed at www.sedar.com. Except as may be required by applicable securities laws, Lightstream assumes no obligation to publicly update or revise any forward-looking statements made herein or otherwise, whether as a result of new information, future events or otherwise.





John D. Wright
President and Chief Executive Officer
403.268.7800
Peter D. Scott
Senior Vice President and Chief Financial Officer
403.268.7800
Annie C. Belecki
General Counsel
403.268.7800
403.218.6075
[email protected]
www.lightstreamresources.com




Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.23
LTS's PB Ratio is ranked lower than
52% of the 670 Companies
in the Global Capital Markets industry.

( Industry Median: 1.27 vs. LTS: 1.23 )
Ranked among companies with meaningful PB Ratio only.
LTS' s PB Ratio Range Over the Past 10 Years
Min: 0.86  Med: 3.91 Max: 16.98
Current: 1.23
0.86
16.98
PS Ratio 0.39
LTS's PS Ratio is ranked higher than
92% of the 651 Companies
in the Global Capital Markets industry.

( Industry Median: 4.05 vs. LTS: 0.39 )
Ranked among companies with meaningful PS Ratio only.
LTS' s PS Ratio Range Over the Past 10 Years
Min: 0.27  Med: 0.87 Max: 10.1
Current: 0.39
0.27
10.1
Price-to-Free-Cash-Flow 79.67
LTS's Price-to-Free-Cash-Flow is ranked lower than
92% of the 195 Companies
in the Global Capital Markets industry.

( Industry Median: 13.36 vs. LTS: 79.67 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LTS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 3.66  Med: 36.78 Max: 99999999.99
Current: 79.67
3.66
99999999.99
Price-to-Operating-Cash-Flow 31.83
LTS's Price-to-Operating-Cash-Flow is ranked lower than
82% of the 228 Companies
in the Global Capital Markets industry.

( Industry Median: 12.54 vs. LTS: 31.83 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LTS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 3.59  Med: 25.15 Max: 400
Current: 31.83
3.59
400
EV-to-EBIT -37.02
LTS's EV-to-EBIT is ranked lower than
99.99% of the 603 Companies
in the Global Capital Markets industry.

( Industry Median: 15.70 vs. LTS: -37.02 )
Ranked among companies with meaningful EV-to-EBIT only.
LTS' s EV-to-EBIT Range Over the Past 10 Years
Min: -3875.2  Med: -16.5 Max: 472.2
Current: -37.02
-3875.2
472.2
EV-to-EBITDA 20.92
LTS's EV-to-EBITDA is ranked lower than
71% of the 617 Companies
in the Global Capital Markets industry.

( Industry Median: 13.49 vs. LTS: 20.92 )
Ranked among companies with meaningful EV-to-EBITDA only.
LTS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -199.5  Med: 26.2 Max: 406.7
Current: 20.92
-199.5
406.7

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
LTS's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 305 Companies
in the Global Capital Markets industry.

( Industry Median: -1.30 vs. LTS: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LTS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -186.7  Med: -3.95 Max: 0.6
Current: -2.5
-186.7
0.6

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 3.91
LTS's Price-to-Tangible-Book is ranked lower than
82% of the 633 Companies
in the Global Capital Markets industry.

( Industry Median: 1.27 vs. LTS: 3.91 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
LTS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.61  Med: 6.29 Max: 117.86
Current: 3.91
1.61
117.86
Price-to-Intrinsic-Value-Projected-FCF 1.44
LTS's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
57% of the 211 Companies
in the Global Capital Markets industry.

( Industry Median: 1.22 vs. LTS: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
LTS' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0  Med: 3.67 Max: 12.47
Current: 1.44
0
12.47
Price-to-Median-PS-Value 0.42
LTS's Price-to-Median-PS-Value is ranked higher than
88% of the 561 Companies
in the Global Capital Markets industry.

( Industry Median: 1.05 vs. LTS: 0.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LTS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0  Med: 0.83 Max: 10.27
Current: 0.42
0
10.27
Earnings Yield (Greenblatt) % -2.72
LTS's Earnings Yield (Greenblatt) % is ranked lower than
82% of the 831 Companies
in the Global Capital Markets industry.

( Industry Median: 3.74 vs. LTS: -2.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LTS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -2.84  Med: 1.3 Max: 3.1
Current: -2.72
-2.84
3.1

More Statistics

Revenue (TTM) (Mil) $1,128
EPS (TTM) $ -0.32
Beta1.56
Short Percentage of Float3.40%
52-Week Range $1.63 - 2.87
Shares Outstanding (Mil)195.88

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 1,183 1,282
EPS ($) -0.15 -0.09
EPS without NRI ($) -0.15 -0.09
EPS Growth Rate
(Future 3Y To 5Y Estimate)
15.00%
Dividends per Share ($)
» More Articles for LTS

Headlines

Articles On GuruFocus.com
ChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li May 25 2017 
Gladstone Investment Corporation Announces Common Stock Offering May 08 2017 
ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing Apr 27 2017 
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering Apr 19 2017 
Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full Exer Apr 12 2017 
Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering Apr 07 2017 
Securities Service Network Names Joe Simpson Chief Information Officer Mar 31 2017 
Amedica Announces Pricing of $11 Million Public Offering Jul 05 2016 
Lightstream Provides Update on Second Lien Note Interest Payment and Extension of Annual Meeting Dat Jun 14 2016 
Lightstream Announces Semi-Annual Borrowing Base Re-Determination Under Credit Facility May 02 2016 

More From Other Websites
ChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li... May 25 2017
ETFs with exposure to Ladenburg Thalmann Financial Services, Inc. : May 22, 2017 May 22 2017
Securities America Announces 2016 Assistant of the Year May 18 2017
Ladenburg Thalmann Financial Services, Inc. :LTS-US: Earnings Analysis: Q1, 2017 By the Numbers :... May 10 2017
Ladenburg Thalmann Financial Services, Inc. breached its 50 day moving average in a Bearish Manner :... May 10 2017
Ladenburg reports 1Q loss May 09 2017
Ladenburg Thalmann Reports First Quarter 2017 Financial Results May 09 2017
Gladstone Investment Corporation Announces Common Stock Offering May 08 2017
Ladenburg Thalmann Launches Ladenburg Thalmann Annuity Insurance Services May 08 2017
ChromaDex Announces Strategic Investment Led by Mr. Li Ka-shing Apr 27 2017
Ladenburg Thalmann Sends Annual Letter to Shareholders Apr 24 2017
Sunshine Heart Announces Pricing of $8.0 Million Underwritten Public Offering Apr 19 2017
Catalyst Biosciences Announces Closing of a $20.7 Million Underwritten Public Offering and Full... Apr 12 2017
ETFs with exposure to Ladenburg Thalmann Financial Services, Inc. : April 12, 2017 Apr 12 2017
TICC Capital Corp. Completes Public Offering of $64,370,225 6.50% Notes Due 2024 Apr 12 2017
Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering Apr 07 2017
TICC Capital Corp. Prices Public Offering of $57.5 Million 6.50% Notes Due 2024 Apr 04 2017
TICC Capital Corp. Announces Offering of Notes Apr 03 2017
Ladenburg Thalmann Financial Services Inc. Confirms Series A Preferred Stock Monthly Dividends for... Apr 03 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)